Showing posts with label combination improves outcomes in breast cancer patients. Show all posts
Showing posts with label combination improves outcomes in breast cancer patients. Show all posts
Thursday, November 10, 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

›
In continuation of my update on  epirubicin   The study entitled "A phase II neoadjuvant sequential regimen of docetaxel follow...